Compare Amgen, Inc. (AMGN) vs Dollar Tree, Inc. (DLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Dollar Tree, Inc. — how do they compare? Amgen, Inc. trades at $417.51 (market cap $224.14B), while Dollar Tree, Inc. trades at $128.03 (market cap $24.61B). The key difference: Amgen, Inc. is far larger — about 9.1× Dollar Tree, Inc.'s market cap, and Amgen, Inc. pays a 2.43% dividend while Dollar Tree, Inc. pays none. Which is the better fit depends on your goals.
| AMGN | DLTR | |
|---|---|---|
Market Cap | $224.14B | $24.61B |
Sector | Health | Health |
52-Week High | $417.20 | $141.21 |
52-Week Low | $271.18 | $85.04 |
Enterprise Value | $267.45B | $31.20B |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
Dollar Tree (DLTR) trades at $129.37, down 1.17% today but remains in a bullish technical trend with strong support near $128. The company reported a net loss of $3.03B for 2025 due to a significant tax charge, though operating cash flow improved to $2.86B. Recent earnings have consistently beaten estimates, and a new $2.5B share repurchase program signals management confidence.
The outlook is mixed: robust cash generation and positive earnings surprises support upside, but margin pressures from tariffs and intense discount retail competition pose risks. Analyst consensus is a Buy with a $126.69 price target, slightly below current levels, indicating cautious optimism amid operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →
